Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003-2010: Potential Impact of Human Papillomavirus Vaccination
Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003-2010: Potential Impact of Human Papillomavirus Vaccination
复制标题
DOI：
10.2105/ajph.2012.301182
复制
发表时间：
2013-08-01
影响因子：
12.7
通讯作者：
Weinstock, Hillard
中科院分区：
文献类型：
--
作者：
Flagg, Elaine W.;Schwartz, Robert;Weinstock, Hillard
目标。我们在拥有私人保险的大型美国队列中按性别和年龄组估算了 2003 年至 2010 年间肛门生殖器疣的患病率，以发现最有可能受到人乳头瘤病毒 (HPV) 疫苗接种影响的人群中的潜在下降趋势。方法。我们将医疗保健索赔仅限于年龄在 10 岁至 39 岁且在某一年内有连续保险的个人。我们从尖锐湿疣的诊断中得出肛门生殖器疣的诊断，或者是不太特异性的病毒疣诊断或生殖器疣药物结合良性肛门生殖器肿瘤或非宫颈肛门生殖器病变的破坏或切除。结果。 15 至 19 岁女孩的患病率在 2003 年至 2006 年略有上升，然后在 2007 年至 2010 年显着下降； 20 至 24 岁女性中，2003 年至 2007 年有所增加，2009 年保持在同一水平，2010 年有所下降； 2009 年 25 至 39 岁女性的这一数字有所增加，但 2010 年没有增加。对于 15 至 39 岁的男性，2003 年至 2009 年每个 5 岁年龄组的患病率有所增加，但 2010 年没有观察到增加。结论。这些数据表明 15 至 24 岁美国女性中肛门生殖器疣的数量有所减少，该年龄组最有可能受到 HPV 疫苗引入的影响。
Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age group in a large US cohort with private insurance to detect potential decreases among people most likely to be affected by human papillomavirus (HPV) vaccination.Methods. We restricted health care claims to those from individuals aged 10 to 39 years with continuous insurance within a given year. We derived anogenital wart diagnoses from a diagnosis of condyloma acuminata, or either a less specific viral wart diagnosis or genital wart medication combined with either a benign anogenital neoplasm or destruction or excision of a noncervical anogenital lesion.Results. Prevalence increased slightly in 2003 to 2006, then significantly declined in 2007 to 2010 among girls aged 15 to 19 years; increased in 2003 to 2007, remained level through 2009, and declined in 2010 among women aged 20 to 24 years; and increased through 2009 but not in 2010 for women aged 25 to 39 years. For males aged 15 to 39 years, prevalence for each 5-year age group increased in 2003 to 2009, but no increases were observed for 2010.Conclusions. These data indicate reductions in anogenital warts among US females aged 15 to 24 years, the age group most likely to be affected by introduction of the HPV vaccine.